

November 9, 2016

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto,
President, Representative Director & CEO

HEALIOS Announces Execution of a Sublicense Agreement with Takeda Pharmaceutical Company Limited

HEALIOS K.K. (“Healios”) and Takeda Pharmaceutical Company Limited (“Takeda”) executed a non-exclusive sublicense agreement for organ bud formation technology, for which Healios has license with the right to sublicense, for a part of research on the application of iPS cell technology in future drug discovery undertaken by Takeda.

Organ bud formation technology refers to the technology invented in Yokohama City University to generate human organs using pluripotent stem cells, e.g., iPS cells, discovered by Professor Shinya Yamanaka, Center for iPS Cell Research and Application, Kyoto University (“CiRA”). Healios has executed a global exclusive patent license agreement for this technology with Yokohama City University and initiated joint research.

(For more information, please visit <https://www.healios.co.jp/en/development/research/>)

Takeda has been carrying out multiple research projects on application of iPS cells in drug development under a joint research agreement with CiRA on iPS cell research (Takeda-CiRA Joint Program for iPS Cell Applications). One of them has started with Takanori Takebe, Associate Professor at Department of Regenerative Medicine, Yokohama City University Graduate School of Medical Science, who is one of the inventors of organ bud technology, as the principal investigator. Non-exclusive license on research, generation and use of organ buds has been sublicensed from Healios to Takeda with the aim of searching and establishing assessment systems to be utilized for drug development screening and safety tests, as well as performing them using the established assessment system in this project.

Healios will receive a lump-sum payment for this patent sublicense agreement from Takeda, but it has only a minimal effect on its fiscal year 2016 financial performance.

Contact
HEALIOS K.K.
Corporate Communication Group
pr@healios.jp